|Articles|August 9, 2021
- Pharmaceutical Executive-08-01-2021
- Volume 41
- Issue 8
Pharmaceutical Executive, August 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
Why the Pandemic is Rewriting the Biopharma Rule Bookover 4 years ago
Primary Care in Crisis: PCP Navigation in a Specialty Worldover 4 years ago
A Brave New World: Optimizing Access in Wake of COVIDover 4 years ago
By Any Genes Necessary: The Role of MEAs for Gene Therapiesover 4 years ago
A Framework for Future: Strengthening Market Access Competenciesover 4 years ago
A Global Vision for Accessover 4 years ago
Early Payer-Related Lessons for Pharma Post-Aduhelm Approvalover 4 years ago
Biotech Capital Markets Continue to UnderperformNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Patients Avoid Care as Healthcare Costs Rise: Report
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
